Bispecific Antibodies and Autologous Chimeric Antigen Receptor T Cell Therapies for Treatment of Hematological Malignancies

Investigators explored the mechanisms underlying autologous CAR-T therapies and bispecific antibodies, focusing on their clinical application in multiple myeloma, ALL, and non-Hodgkin lymphoma.